Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) just unveiled an update.
Imugene Limited has outlined plans for a new capital raising via a placement or similar issue of securities, detailing the proposed issuance of 66,666,667 ordinary fully paid shares. The company will also issue two tranches of quoted options, each comprising 66,666,667 options with expiries in April 2027 and April 2029 and exercise prices of $0.18 and $0.30 respectively, with the issue slated for 20 March 2026.
The structured mix of equity and options suggests Imugene is seeking to bolster its balance sheet while providing potential upside participation for investors over the medium term. This funding initiative may support the company’s ongoing immuno-oncology development activities and could influence its capital structure and market liquidity ahead of key operational milestones.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.21 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australia-listed biotechnology company focused on developing immuno-oncology therapies. Its primary activities center on researching and advancing novel cancer treatments, with its securities traded on the ASX under the code IMU, giving it access to public capital markets to fund ongoing development programs.
Average Trading Volume: 1,405,648
Technical Sentiment Signal: Sell
Current Market Cap: A$73.95M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.